Koichi Takahashi

Hematology

1515 Holcombe Blvd Unit 428
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 258 publications

Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

Journal: Nature

Published: August 18, 2026

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 23, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Final results of a phase II study of the combination of azacitidine and ruxolitinib in patients with myelofibrosis.

Journal: Haematologica

Published: May 04, 2026

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Journal: Journal of hematology & oncology

Published: March 25, 2026

Clonal dynamics of CH in CLL.

Clonal dynamics of CH in CLL.

Journal: Blood

Published: March 19, 2026

Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia.

Treatment in Clinical Trials Could Mitigate Socioeconomic and Racial Disparities in Acute Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 12, 2026

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Journal: Cancer

Published: January 28, 2026

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.

Journal: Leukemia

Published: December 10, 2025

Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia.

Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia.

Journal: JCO precision oncology

Published: December 10, 2025

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

Journal: British journal of haematology

Published: December 08, 2025

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Journal: Blood cancer discovery

Published: October 18, 2025

Showing 1-12 of 258

Last Updated: 09/26/2026